Central Bank & Trust Co. Grows Stake in ABIOMED, Inc. (NASDAQ:ABMD)

Central Bank & Trust Co. grew its holdings in ABIOMED, Inc. (NASDAQ:ABMD) by 17.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 7,427 shares of the medical equipment provider’s stock after acquiring an additional 1,093 shares during the quarter. Central Bank & Trust Co.’s holdings in ABIOMED were worth $1,321,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ABMD. Executive Wealth Management LLC grew its stake in ABIOMED by 100.0% during the 2nd quarter. Executive Wealth Management LLC now owns 100 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 50 shares during the last quarter. Kistler Tiffany Companies LLC purchased a new position in ABIOMED during the 3rd quarter worth approximately $34,000. Tompkins Financial Corp purchased a new position in ABIOMED during the 2nd quarter worth approximately $39,000. FTB Advisors Inc. purchased a new position in ABIOMED during the 2nd quarter worth approximately $48,000. Finally, Captrust Financial Advisors grew its stake in ABIOMED by 484.8% during the 2nd quarter. Captrust Financial Advisors now owns 193 shares of the medical equipment provider’s stock worth $50,000 after buying an additional 160 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

In other news, COO David M. Weber sold 8,095 shares of ABIOMED stock in a transaction on Monday, August 5th. The stock was sold at an average price of $206.26, for a total value of $1,669,674.70. Following the completion of the sale, the chief operating officer now owns 132,913 shares of the company’s stock, valued at $27,414,635.38. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 3.40% of the company’s stock.

A number of analysts have weighed in on ABMD shares. Morgan Stanley cut ABIOMED from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $325.00 to $215.00 in a research report on Thursday, August 1st. Guggenheim cut ABIOMED from a “buy” rating to a “neutral” rating in a research report on Friday, August 2nd. TheStreet cut ABIOMED from a “b-” rating to a “c+” rating in a research report on Thursday, August 22nd. ValuEngine raised ABIOMED from a “sell” rating to a “hold” rating in a research report on Wednesday, September 4th. Finally, William Blair reaffirmed a “buy” rating on shares of ABIOMED in a research report on Monday, September 30th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. ABIOMED presently has an average rating of “Hold” and an average price target of $316.50.

Shares of ABMD traded up $2.13 during mid-day trading on Thursday, hitting $180.86. The company’s stock had a trading volume of 3,936 shares, compared to its average volume of 623,331. The firm has a 50-day simple moving average of $179.21 and a 200 day simple moving average of $231.51. The firm has a market capitalization of $7.75 billion, a P/E ratio of 50.28, a P/E/G ratio of 1.48 and a beta of 0.41. ABIOMED, Inc. has a 1-year low of $155.02 and a 1-year high of $427.70.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings results on Thursday, August 1st. The medical equipment provider reported $1.00 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.01. The company had revenue of $207.70 million during the quarter, compared to the consensus estimate of $210.96 million. ABIOMED had a return on equity of 19.84% and a net margin of 32.35%. ABIOMED’s revenue was up 15.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.95 earnings per share. Sell-side analysts anticipate that ABIOMED, Inc. will post 4.27 EPS for the current fiscal year.

ABIOMED Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Recommended Story: How does a margin account work?

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.